IXICO plc (PHYOF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.43 Million USD | -1804.37% |
| 2022 | 123.87 Thousand USD | -86.83% |
| 2021 | 940.34 Thousand USD | 208.21% |
| 2020 | 305.1 Thousand USD | 225.68% |
| 2019 | -242.76 Thousand USD | 86.19% |
| 2018 | -1.75 Million GBP | 33.56% |
| 2017 | -2.64 Million GBP | 33.4% |
| 2016 | -3.97 Million GBP | -184.96% |
| 2015 | -1.39 Million GBP | 27.39% |
| 2014 | -1.91 Million GBP | 62.94% |
| 2013 | -5.18 Million GBP | 44.28% |
| 2012 | -9.29 Million GBP | -8.76% |
| 2011 | -8.54 Million GBP | -89.81% |
| 2010 | -4.5 Million GBP | -2.78% |
| 2009 | -4.38 Million GBP | -59.66% |
| 2008 | -2.74 Million GBP | 0.0% |
| 2007 | - GBP | 100.0% |
| 2006 | -6.62 Million GBP | -68.16% |
| 2005 | -3.93 Million GBP | 43.7% |
| 2004 | -6.99 Million GBP | -17.5% |
| 2003 | -5.95 Million GBP | -38.08% |
| 2002 | -4.31 Million GBP | -21.98% |
| 2001 | -3.53 Million GBP | -44.34% |
| 2000 | -2.44 Million GBP | 27.44% |
| 1999 | -3.37 Million GBP | 13.95% |
| 1998 | -3.92 Million GBP | -10.42% |
| 1997 | -3.55 Million GBP | -418.54% |
| 1996 | -685 Thousand GBP | -294.05% |
| 1995 | 353 Thousand GBP | 117.06% |
| 1994 | -2.06 Million GBP | -193.06% |
| 1993 | -706 Thousand GBP | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.32 Million USD | 0.0% |
| 2023 FY | -2.11 Million USD | -1804.37% |
| 2023 Q2 | -1.34 Million USD | 0.0% |
| 2023 Q4 | -887.94 Thousand USD | 0.0% |
| 2022 Q4 | 486.57 Thousand USD | 0.0% |
| 2022 Q2 | -231.14 Thousand USD | 0.0% |
| 2022 FY | 123.87 Thousand USD | -86.83% |
| 2021 Q2 | 572.57 Thousand USD | 0.0% |
| 2021 Q4 | 428.4 Thousand USD | 0.0% |
| 2021 FY | 940.34 Thousand USD | 208.21% |
| 2020 Q4 | 183.57 Thousand USD | 0.0% |
| 2020 FY | 305.1 Thousand USD | 225.68% |
| 2020 Q2 | 133.91 Thousand USD | 0.0% |
| 2019 FY | -242.76 Thousand USD | 86.19% |
| 2019 Q4 | -32.03 Thousand USD | 0.0% |
| 2018 FY | -1.75 Million GBP | 33.56% |
| 2017 FY | -2.64 Million GBP | 33.4% |
| 2016 FY | -3.97 Million GBP | -184.96% |
| 2015 FY | -1.39 Million GBP | 27.39% |
| 2014 FY | -1.91 Million GBP | 62.94% |
| 2013 FY | -5.18 Million GBP | 44.28% |
| 2012 FY | -9.29 Million GBP | -8.76% |
| 2011 FY | -8.54 Million GBP | -89.81% |
| 2010 FY | -4.5 Million GBP | -2.78% |
| 2009 FY | -4.38 Million GBP | -59.66% |
| 2008 FY | -2.74 Million GBP | 0.0% |
| 2007 FY | - GBP | 100.0% |
| 2006 FY | -6.62 Million GBP | -68.16% |
| 2005 FY | -3.93 Million GBP | 43.7% |
| 2004 FY | -6.99 Million GBP | -17.5% |
| 2003 FY | -5.95 Million GBP | -38.08% |
| 2002 FY | -4.31 Million GBP | -21.98% |
| 2001 FY | -3.53 Million GBP | -44.34% |
| 2000 FY | -2.44 Million GBP | 27.44% |
| 1999 FY | -3.37 Million GBP | 13.95% |
| 1998 FY | -3.92 Million GBP | -10.42% |
| 1997 FY | -3.55 Million GBP | -418.54% |
| 1996 FY | -685 Thousand GBP | -294.05% |
| 1995 FY | 353 Thousand GBP | 117.06% |
| 1994 FY | -2.06 Million GBP | -193.06% |
| 1993 FY | -706 Thousand GBP | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -7.606% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 71.513% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 91.948% |
| Nascent Biotech, Inc. | -2.22 Million USD | 35.557% |
| Rebus Holdings, Inc. | -664 Thousand USD | -116.416% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.756% |
| Qrons Inc. | -643.67 Thousand USD | -123.249% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -268.868% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 97.411% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -245.866% |
| Skye Bioscience, Inc. | -13.67 Million USD | 89.489% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 97.998% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 129.238% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -449.047% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.105% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 49.588% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 6.448% |
| Mesoblast Limited | -84.14 Million USD | 98.292% |
| Marizyme, Inc. | -34.08 Million USD | 95.784% |
| Genus plc | 6.4 Million USD | 122.453% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 114.75% |
| Pharming Group N.V. | -4.87 Million USD | 70.551% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 27.661% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -54.287% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 82.79% |
| ContraFect Corporation | -56.88 Million USD | 97.474% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 68.45% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -2.497% |
| IMV Inc. | -38.67 Million USD | 96.284% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 47.761% |
| MultiCell Technologies, Inc. | -722.81 USD | -198707.432% |
| ONE Bio Corp. | 13.68 Million USD | 110.503% |
| Accustem Sciences Inc. | -3.74 Million USD | 61.643% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 97.564% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -197.477% |
| Q BioMed Inc. | -3.44 Million USD | 58.295% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 140.593% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 45.31% |
| Biomind Labs Inc. | -1 Million USD | -42.333% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 97.386% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 50.47% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 78.385% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 22.923% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -4697.676% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 90.945% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 25.645% |
| GB Sciences, Inc. | -1.42 Million USD | -1.161% |
| Alpha Cognition Inc. | -9.7 Million USD | 85.194% |
| HST Global, Inc. | -140.9 Thousand USD | -919.822% |
| CSL Limited | 3.7 Billion USD | 100.039% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -27.744% |
| Halberd Corporation | -75.05 Thousand USD | -1814.724% |
| Enzolytics Inc. | -2.14 Million USD | 33.125% |
| Agentix Corp. | -1.37 Million USD | -4.756% |
| Resverlogix Corp. | -12.74 Million USD | 88.729% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 54.644% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.662% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -37.644% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 50.778% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 9.013% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 57.797% |
| AVAX Technologies, Inc. | 6.69 Million USD | 121.471% |
| Zenith Capital Corp. | -8.94 Million USD | 83.932% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.654% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -8148.665% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 41.474% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -737.854% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 28.32% |
| Kadimastem Ltd | -3.04 Million USD | 52.734% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -46.029% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -14.411% |
| BioStem Technologies, Inc. | -7.77 Million USD | 81.527% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -691.801% |
| LadRx Corporation | -3.82 Million USD | 62.418% |
| Cell Source, Inc. | -4.32 Million USD | 66.777% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -109.186% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -109.186% |
| NovAccess Global Inc. | -2.46 Million USD | 41.745% |
| Affymax, Inc. | -15.04 Million USD | 90.449% |
| Itoco Inc. | -919.14 Thousand USD | -56.342% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 66.096% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -28.418% |
| Mobile Lads Corp. | -554.55 Thousand USD | -159.129% |
| CytoDyn Inc. | -18.05 Million USD | 92.042% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -5609.178% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -552.95% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -154.461% |
| SYBLEU INC | -149.18 Thousand USD | -863.266% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 20.884% |
| International Stem Cell Corporation | -663 Thousand USD | -116.742% |
| Bioxytran, Inc. | -3.82 Million USD | 62.384% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2629.863% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -6964.897% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 96.038% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 11.187% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -95.288% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 53.809% |
| Neutra Corp. | -229.48 Thousand USD | -526.182% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 91.807% |
| PureTech Health plc | -146.19 Million USD | 99.017% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 93.314% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 84.859% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.82% |
| CSL Limited | 3.81 Billion USD | 100.038% |
| Cellectis S.A. | -108.85 Million USD | 98.68% |